FDA gives green light to Guardant Health’s Shield blood test: A game-changer in colorectal cancer screening and Medicare coverage
In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved Guardant Health, Inc.'s Shield blood test as a primary screening option for ... Read More
FDA approves Guardant360 CDx assay as companion diagnostic for Menarini’s ORSERDU for metastatic breast cancer
Guardant Health, an oncology company, has secured the approval of the US Food and Drug Administration (FDA) for the company’s Guardant360 CDx liquid biopsy assay ... Read More